Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.

ESMO Open · 2025 · PMC12684762 · PMID 41320342

Europe PMC DOI

hedged sentence

0.0260

closest p · 0.5× alpha

0.0260

boldest claim

The sentences

a positive trendP = 0.026actually significant

• A positive trend for OS in favor of ribociclib continues to emerge (hazard ratio 0.800, 95% CI 0.637-1.003, nominal one-sided P = 0.026). • No new safety signals for causes of deaths or secondary primary malignancies were identified with this updated analysis.

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.